

Akebia Therapeutics (USA): Merger with Keryx Biopharmaceuticals (USA)

Changes in Russell Equal Weight Index Series

11 December 2018

Subject to the completion of the merger between Akebia Therapeutics (USA, constituent) and Keryx Biopharmaceuticals (USA, constituent), please see details of affected indexes and effective dates below:

Index	Effective From Start of Trading
Russell 2000 Equal Weight	14 December 2018

*The number of shares is based on the merger terms of 0.37433 of a share of Akebia Therapeutics for every Akebia Therapeutics share held.

In the absence of an active market, Keryx Biopharmaceuticals will be removed from the index using the merger terms of 0.37433 of a share of Akebia Therapeutics.

For further information please contact FTSE Russell Client Services at info@ftserussell.com or call:

Australia	+1800 653 680
Hong Kong	+852 2164 3333
Japan	+81 3 4563 6346
London	+44 (0) 20 7866 1810
New York	+1866 551 0617

Alternatively please visit our website at www.ftserussell.com

Terms of Use | Copyright © 2018 FTSE Russell